Optimizing Triple Therapy for Resistant Hypertension

Pharmacologic Foundations

Adding a thiazide‑like diuretic (chlorthalidone or indapamide) completes the first‑line triple‑therapy regimen (ARB + CCB + thiazide‑like diuretic) recommended for resistant hypertension. 1
Thiazide‑like diuretics achieve greater blood‑pressure reduction and provide superior cardiovascular protection compared with thiazide‑type agents such as hydrochlorothiazide. 1, 2
Chlorthalidone is preferred over hydrochlorothiazide because of its higher efficacy in lowering systolic and diastolic pressure. 1

Apparent resistant hypertension is present when blood pressure remains uncontrolled on two agents (ARB + CCB); the formal definition requires uncontrolled BP on three agents, including a diuretic. 1, 2

Before escalating beyond triple therapy, pseudoresistance must be excluded by 24‑hour ambulatory blood‑pressure monitoring (or home monitoring if ABPM unavailable). 2
Direct assessment of medication adherence is essential to rule out non‑adherence as a cause of uncontrolled pressure. 2
A comprehensive medication review should identify drugs that can blunt antihypertensive effects (e.g., NSAIDs, decongestants, systemic steroids). 1
Screening for secondary causes—primary aldosteronism, obstructive sleep apnea, chronic kidney disease, and renovascular disease—should be performed because they are more prevalent in resistant hypertension. 1

Sodium intake should be limited to < 2400 mg per day to enhance pharmacologic control. 2
Weight reduction is advised for patients with obesity, as excess body weight is a major risk factor for resistant hypertension. 1
Regular aerobic physical activity contributes to additional blood‑pressure lowering. 2
Ensuring ≥ 6 hours of uninterrupted sleep each night supports optimal BP management. 2

If estimated glomerular filtration rate (eGFR) is ≥ 45 mL/min/1.73 m², add spironolactone as the preferred fourth‑line agent; this is a Class I, Level B‑R recommendation from the 2025 ACC/AHA hypertension guideline. 1
When spironolactone is not tolerated, alternative mineralocorticoid receptor antagonists such as eplerenone or amiloride may be used. 2
If an MRA cannot be employed or fails to achieve target BP, consider a β‑blocker (e.g., metoprolol succinate, bisoprolol) or a combined α/β blocker (e.g., labetalol, carvedilol) especially when heart rate > 70 bpm. 2
An α‑blocker (doxazosin) is an additional option for patients who cannot receive β‑blockade. 2
Central α‑agonists (clonidine patch weekly or guanfacine at bedtime) are appropriate when β‑blockers are contraindicated. 2
For refractory cases, vasodilators such as hydralazine (starting 25 mg three times daily, titrated upward) may be introduced, followed by minoxidil (starting 2.5 mg two to three times daily) if hydralazine is insufficient. 2

Do not substitute hydrochlorothiazide for a thiazide‑like diuretic in the triple‑therapy regimen, as it provides inferior BP control. 1
Avoid adding a fourth antihypertensive agent before confirming true resistance with out‑of‑office BP monitoring and adherence verification. 2
When initiating MRAs, closely monitor serum potassium and renal function, particularly in older adults and those with eGFR 45–60 mL/min/1.73 m². 1
Screen for primary aldosteronism before starting spironolactone, given its status as the most common secondary cause of resistant hypertension. 1

Patients aged ≥ 70 years have an increased risk of resistant hypertension due to age‑related arterial stiffness and a higher prevalence of secondary etiologies. 1
In older individuals, vigilant monitoring for orthostatic hypotension is required when intensifying antihypertensive therapy. 2